Full history for every metric is available with a Kvantra account
LakeShore Biopharma Co., Ltd (LSB)
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | - | 257 | 503 | 687 | 573 | 615 | 577 |
| Operating profit | CNY m | -86 | - | |||||
| Net profit | CNY m | - | -192 | -237 | -145 | -433 | -100 | -434 |
| EPS reported | CNY | -0.94 | -4.54 | |||||
| Operating cashflow per share | CNY | -1.13 | -1.13 | |||||
| Capex per share | CNY | 0.17 | 0.17 | |||||
| FCF per share | CNY | -1.30 | -1.30 | |||||
| Free cash flow | CNY m | -139 | 0 | |||||
| Net debt | CNY m | 386 | 386 | |||||
| Book value equity | CNY m | 500 | 500 | |||||
| Book value per share | CNY | 4.67 | 5.00 | |||||
| Number of shares | m | 106.92 | 99.99 | |||||
| DPS (TTM paid) | CNY | 0.00 | 0.00 |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 3.80 | 0.35 | |||||
| P/S LTM | x | 3.09 | 0.30 | |||||
| P/FCF LTM | x | -13.69 | -1.25 | |||||
| EV/EBITDA LTM | x | -47.12 | -1.78 | |||||
| EV/Sales LTM | x | 3.72 | 0.97 | |||||
| Earnings Yield LTM | % | -5.26% | -22.25% | |||||
| FCF Yield | % | -7.30% | 0.00% | |||||
| Quality | ||||||||
| ROE | % | -20.01% | -18.43% | |||||
| ROIC | % | -9.15% | -9.15% | |||||
| Operating margin | % | -14.03% | -14.03% | |||||
| Gross margin | % | 82.47% | 82.47% | |||||
| FCF/Sales | % | -22.58% | -22.58% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +7.24% | -16.56% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.34 | 0.00 | |||||
| Net Debt/EBITDA | x | -7.96 | -7.96 | |||||
| EBIT/Net interest | x | -5.48 | -5.48 | |||||
| Net debt/market cap | % | 20.30% | 222.72% | |||||
| Net debt/Equity | x | 0.77 | 0.77 | |||||
| Gross debt/equity | x | 0.83 | 0.83 | |||||
Company overview
LakeShore Biopharma Co., Ltd is a biopharmaceutical firm focused on the discovery, advancement, manufacturing, and marketing of vaccines and therapeutic biologics. Its primary targets are infectious diseases and various forms of cancer. At the core of its innovation is a proprietary PIKA immunomodulating technology platform, which underpins its product pipeline, featuring a PIKA rabies vaccine, a PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. The company maintains an international presence, conducting operations across China, the United States, Singapore, the United Arab Emirates, and the Philippines. Originally founded in 2002 and based in Beijing, China, the entity was known as YS Biopharma Co., Ltd until it officially changed its name to LakeShore Biopharma Co., Ltd in May 2024.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
LakeShore Biopharma Co., Ltd (LSB)
LakeShore Biopharma Co., Ltd is a biopharmaceutical firm focused on the discovery, advancement, manufacturing, and marketing of vaccines and therapeutic biologics. Its primary targets are infectious diseases and various forms of cancer. At the core of its innovation is a proprietary PIKA immunomodulating technology platform, which underpins its product pipeline, featuring a PIKA rabies vaccine, a PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. The company maintains an international presence, conducting operations across China, the United States, Singapore, the United Arab Emirates, and the Philippines. Originally founded in 2002 and based in Beijing, China, the entity was known as YS Biopharma Co., Ltd until it officially changed its name to LakeShore Biopharma Co., Ltd in May 2024.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free